Abstract
Objective
Design and Setting
Participants
Measurements
Results
Conclusions
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the American Medical Directors AssociationReferences
- Drug Safety Communication: Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist).(Available at:) (Accessed February 3, 2013)
- Zolpidem and zopiclone impair similarly monotonous driving performance after a single nighttime intake in aged subjects.Psychopharmacology. 2011; 214: 699-706
- Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem.J Sleep Res. 2009; 18: 387-396
- Gender differences in highway driving performance after administration of sleep medication: A review of the literature.Traffic Inj Prev. 2012; 13: 286-292
- Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate.Clin Pharmacol Ther. 2004; 76: 467-479
- Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits.BMJ. 2005; 331: 1169
- Hip fracture incidence and mortality in New England.Epidemiology. 1991; 2: 116-122
- Zolpidem use and hip fractures in older people.J Am Geriatr Soc. 2001; 49: 1685-1690
- Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents.JAMA Intern Med. 2013; 173: 754-761
- Risk of fractures requiring hospitalization after an initial prescription for zolpidem, alprazolam, lorazepam, or diazepam in older adults.J Am Geriatr Soc. 2011; 59: 1883-1890
- Zolpidem use and risk of fracture in elderly insomnia patients.J Prev Med Public Health. 2012; 45: 219-226
- Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults.Pharmacoepidemiol Drug Saf. 2010; 19: 1248-1255
- Correlation between use of zopiclone and risk of hip fracture in elderly adults: A case-control study in Taiwan.J Am Geriatr Soc. 2015; 63: 2534-2537
- Incidence and remission of insomnia among elderly adults: An epidemiologic study of 6,800 persons over three years.Sleep. 1999; 22: S366-S372
- Non-benzodiazepine hypnotics: Do they work for insomnia?.BMJ. 2013; 346: e8699
- Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration.BMJ. 2012; 345: e8343
- Nursing home residents and enrollment in Medicare Part D.J Am Geriatr Soc. 2009; 57: 1902-1907
- Long-Term Care Facility Resident Assessment Instrument 2.0 User's Manual.(Available at:) (Accessed May 27, 2015)
- A comprehensive clinical assessment tool to inform policy and practice: Applications of the minimum data set.Med Care. 2004; 42: III50-III59
- The case-crossover design: A method for studying transient effects on the risk of acute events.Am J Epidemiol. 1991; 133: 144-153
- Effects of mixing techniques on vancomycin-impregnated polymethylmethacrylate.J Arthroplasty. 2011; 26: 1562-1566
- Identification of fractures from computerized Medicare files.J Clin Epidemiol. 1992; 45: 703-714
- Comparing methods to identify hip fracture in a nursing home population using Medicare claims.Osteoporos Int. 2011; 22: 57-61
- Evaluating medication effects outside of clinical trials: New-user designs.Am J Epidemiol. 2003; 158: 915-920
- Scaling ADLs within the MDS.J Gerontol A Biol Sci Med Sci. 1999; 54: M546-M553
- Risk factors for adverse drug events among nursing home residents.Arch Intern Med. 2001; 161: 1629-1634
- 2015 updated Beers Criteria for potentially inappropriate medication use in older adults.J Am Geriatr Soc. 2015; 63: 2227-2246
- Misclassification of current benzodiazepine exposure by use of a single baseline measurement and its effects upon studies of injuries.Pharmacoepidemiol Drug Saf. 2002; 11: 663-669
- Effects of a geriatric intervention aiming to improve quality care in nursing homes on benzodiazepine use and discontinuation.Br J Clin Pharmacol. 2016; 81: 759-767
- Potentially inappropriate medications in the elderly in Korean long-term care facilities.Drugs Real World Outcomes. 2015; 2: 355-361
Article info
Publication history
Footnotes
This work was partially funded through research grants from the National Institute on Aging (5P01AG027296-05, K23AG033204, and 5R01AG045441). A.R.Z. is supported by Agency for Healthcare Research and Quality award 5K12HS022998.
V.M.'s research is in a related area to that of several different paid activities. V.M. also periodically serves as a paid speaker at national conferences where he discusses trends and research findings in long-term and post-acute care. V.M. holds stock of unknown value in PointRight, Inc., an information services company providing advice and consultation to various components of the long-term care and post-acute care industry, including suppliers and insurers. PointRight sells information on the measurement of nursing home quality to nursing homes and liability insurers. V.M. was a founder of the company but has subsequently divested much of his equity in the company and relinquished his seat on board. In addition, V.M. Chairs the Independent Quality Committee for HRC Manor Care, Inc., a nursing home chain, for which he receives compensation in the $20,000 to $40,000 range. V.M. also serves as chair of a Scientific Advisory Committee for NaviHealth, a post-acute care service organization, for which he also receives compensation in the $20,000 to $40,000 per year range. V.M. serves as a Technical Expert Panel member on several Centers for Medicare/Medicaid quality measurement panels. V.M. is a member of the board of directors of Tufts Health Plan Foundation; Hospice Care of Rhode Island; and The Jewish Alliance of Rhode Island. D.D.D. is an employee of Optum and stockholder in UnitedHealth Group, Optum's parent company. No other conflicts of interest to disclose.
